Quarterly report · Q2
2372.TEDINET S100PFYJ
Period2022-04-01 → 2022-09-30
Filed2022-11-04
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥15.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥858m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥994m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥723m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥721m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥30.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥22.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.5bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.0bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.0bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥653m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥740m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥164.17 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.8 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥162.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.99 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.5 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥163.91 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥162.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.85 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 39.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.4% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥68m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥118m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥673m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥619m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥618m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥181m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥88m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥82m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥953m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥503m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥449m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥24m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥61m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥601m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥641m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥32m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥100m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥492m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥492m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥658m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥294m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥291m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥311m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥29m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥240m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥856m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥497m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥359m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥123m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥77m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥7.3bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥6.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥468m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥7.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥6.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥492m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 548
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 123000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1616000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -100000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1516000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -658000000 | JPY |
| Operating income | Prior1YTDDuration | 858000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 5747000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | 2741000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | 618000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 503000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 9610000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 28000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 9639000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 9639000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 61000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | 88000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 449000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 601000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 39000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 641000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -641000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 5808000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | 2830000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | 619000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 953000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 10211000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 68000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10280000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -641000000 | JPY |
| Net sales | CurrentYTDDuration | 9639000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000SMOReportableSegmentsMember | 3275000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000CROReportableSegmentsMember | 82000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000AdvancedMedicalReportableSegmentsMember | -181000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05352-000MedicalSupportReportableSegmentsMember | 24000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 3201000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -118000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 3083000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -673000000 | JPY |
| Operating income | CurrentYTDDuration | 2409000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-04 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第26期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社アイロムグループ | |
| Company name in english cover page | FilingDateInstant | I'rom Group Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 森 豊隆 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |